BACKGROUND: Thrombocytopenia in pregnancy is the second most common haematologic complications seen, with varying aetiologies. Antibodies to human platelet antigens can result in thrombocytopaenia in pregnancy. These antibodies could have been acquired from exposure to fetal antigen in previous pregnancies, or via blood transfusions. The alloantibodies can also destroy fetal platelets resulting in fetomaternal alloimmune thrombocytopaenia. AIMS AND OBJECTIVES: The study was aimed at determining the prevalence of thrombocytopaenia in pregnant women and screening for alloantibodies to human platelet antigens in pregnant women with thrombocytopaenia. METHODS: Data was collected using a self administered questionnaire. Three milliliters of EDTA blood sample was collected from each participant for full blood count. The platelet count for each participant was determined. The pregnant women with thrombocytopaenia as well as twenty-six pregnant women with normal platelet counts (control) had their plasma tested for alloantibodies using Monoclonal Antibody-specific Immobilization of Platelet Antigen kit (MAIPA).